Pre-Launch Meeting

Stefan Gold • April 30, 2025

The consortium held a pre-launch meeting at Lake Wannsee

On April 28-29, 2025, partner clinics from across Europe gathered at the Blumenfisch guesthouse on Lake Wannsee in Berlin for the first coordination meeting of the EU-PEARLDIVER Platform Trial. Representatives from Aarhus, Barcelona, Berlin, Cologne, Helsinki, London, Milan, Rotterdam, and Vienna came together to set the course for this multinational European trial.


The EU-PEARLDIVER project is dedicated to the urgently needed improvement of therapeutic options for treatment-resistant depression. The study, funded by Wellcome, brings together the scientific and clinical expertise of leading European university hospitals to advance new therapies to patients more quickly and efficiently. Using a platform trial design, this project will allow a variety of treatment options to be tested simultaneously for efficacy and safety, thereby enabling clinically relevant findings to be obtained more quickly.

Public Consultation

August 17, 2025
We are announcing our first public consultation on EU-PEARLDIVER’s master protocol, its planned outcome measures, and our authorship & publication policy. Between September 10, 2025 and December 12, 2025, we welcome your input on the trial's draft documents. The documents can be found under resources and are also linked in the header above. If you would like to send us your thoughts, please complete the provided commentary template . After the end of the public consultation period, we will publish a list of all the comments received along with the consortium’s decision and reasoning. All individuals providing responses will be acknowledged on our website. In addition, our signature red beanies will be given away in a raffle among the respondents to our consultation. We are also considering additional suggestions for treatments to be evaluated in this trial, including candidates for the first two oral drugs, using our drug suggestion template . Funding for running these two drugs is already provided by Wellcome and a decision will be made by December 31, 2025. A current list of candidate drugs under consideration can be found here .

Perspective on platform trials published

By Stefan Gold • March 25, 2025
Our consortium led an international group of clinicians, experts by experience, and methodologists to summarize the potential for platform trials to transform the evidence landscape in mental health. The paper also reviews currently planned and ongoing platform trials in psychosis, post traumatic stress disorder, and depression, including a feature of EU-PEARLDIVER. The paper was published in Nature Mental Health on March 14, 2025. Free to read link: https://rdcu.be/ecSMq